Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.

Double multiply exposure portrait of a dreamy cute woman meditating outdoors with eyes closed, combined with photograph of nature, sunrise or sunset, closeup. Migraine prevention
Nurtec ODT is a fast-dissolving tablet designed for rapid migraine relief • Source: Shutterstock

Biohaven Pharmaceutical Holding Co. Ltd.’s oral calcitonin gene-related peptide (CGRP) inhibitor Nurtec ODT (rimegepant) will soon be the third new therapy to launch this year as an acute treatment for migraine attacks now that the US Food and Drug Administration has approved the drug.

New Haven, CT-based Biohaven announced the approval on 27 February and the company plans to launch the drug in early...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip